Tags

Type your tag names separated by a space and hit enter

Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome.
Postgrad Med. 2008 Jul 31; 120(2):E01-7.PM

Abstract

Obesity is currently a worldwide epidemic, and will likely only increase in prevalence in the coming years. The incidence of the metabolic syndrome (MetS) seems to be paralleling obesity. The MetS is strongly linked to insulin resistance, abdominal obesity, diabetes mellitus, and dyslipidemia. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and the MetS. Although not currently a formal component of the MetS, data suggest a very strong correlation between NAFLD and the MetS; insulin resistance appears to be the common factor. Nonalcoholic steatohepatitis (NASH) is a more advanced stage in the spectrum of NAFLD, which can progress to cirrhosis. Management strategies for NAFLD are conceivably similar to those for the MetS, which focus on lifestyle measures aimed at weight reduction and maintenance. The purpose of this review is to highlight the growing epidemic of obesity and the MetS, and the strong likelihood of an increase in the prevalence of the already widely existent combination of NAFLD/NASH. This article describes pharmacological treatments including novel therapies aimed at the hepatic pathophysiologic process, as well as surgical options. The increasing prevalence of obesity and the MetS places a large population at risk for developing hepatic failure. Therefore, NAFLD must be acknowledged as a major worldwide public health concern.

Authors+Show Affiliations

Department of Medicine, St. Joseph Hospital, Milwaukee, WI, 53210, USA. daramsr@hotmail.com.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18654060

Citation

Boppidi, Hima, and Sumanth R. Daram. "Nonalcoholic Fatty Liver Disease: Hepatic Manifestation of Obesity and the Metabolic Syndrome." Postgraduate Medicine, vol. 120, no. 2, 2008, pp. E01-7.
Boppidi H, Daram SR. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med. 2008;120(2):E01-7.
Boppidi, H., & Daram, S. R. (2008). Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgraduate Medicine, 120(2), E01-7. https://doi.org/10.3810/pgm.2008.07.1800
Boppidi H, Daram SR. Nonalcoholic Fatty Liver Disease: Hepatic Manifestation of Obesity and the Metabolic Syndrome. Postgrad Med. 2008 Jul 31;120(2):E01-7. PubMed PMID: 18654060.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. AU - Boppidi,Hima, AU - Daram,Sumanth R, Y1 - 2008/07/31/ PY - 2008/7/26/pubmed PY - 2008/10/22/medline PY - 2008/7/26/entrez SP - E01 EP - 7 JF - Postgraduate medicine JO - Postgrad Med VL - 120 IS - 2 N2 - Obesity is currently a worldwide epidemic, and will likely only increase in prevalence in the coming years. The incidence of the metabolic syndrome (MetS) seems to be paralleling obesity. The MetS is strongly linked to insulin resistance, abdominal obesity, diabetes mellitus, and dyslipidemia. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and the MetS. Although not currently a formal component of the MetS, data suggest a very strong correlation between NAFLD and the MetS; insulin resistance appears to be the common factor. Nonalcoholic steatohepatitis (NASH) is a more advanced stage in the spectrum of NAFLD, which can progress to cirrhosis. Management strategies for NAFLD are conceivably similar to those for the MetS, which focus on lifestyle measures aimed at weight reduction and maintenance. The purpose of this review is to highlight the growing epidemic of obesity and the MetS, and the strong likelihood of an increase in the prevalence of the already widely existent combination of NAFLD/NASH. This article describes pharmacological treatments including novel therapies aimed at the hepatic pathophysiologic process, as well as surgical options. The increasing prevalence of obesity and the MetS places a large population at risk for developing hepatic failure. Therefore, NAFLD must be acknowledged as a major worldwide public health concern. SN - 1941-9260 UR - https://www.unboundmedicine.com/medline/citation/18654060/Nonalcoholic_fatty_liver_disease:_hepatic_manifestation_of_obesity_and_the_metabolic_syndrome_ L2 - http://www.tandfonline.com/doi/full/10.3810/pgm.2008.07.1800 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.